ASTRAZENECA RECEIVES COMPLETE RESPONSE LETTER FROM US FDA

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

May 27, 2016 at 2:15 AM

ASTRAZENECA RECEIVES COMPLETE RESPONSE LETTER FROM US FDA FOR SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) FOR ORAL SUSPENSION FOR TREATMENT OF HYPERKALAEMIA

27 May 2016 AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. The CRL refers to observations arising from a pre-approval manufacturing inspection. The FDA also acknowledged receipt of recently-submitted data which it has yet to review. The CRL does not require the generation of new clinical data. AstraZeneca and ZS Pharma are evaluating the content of the CRL and will work closely with the FDA to determine the appropriate next steps for the NDA. AstraZeneca remains committed to the development of sodium zirconium cyclosilicate as a treatment option for patients with hyperkalaemia. Interactions are ongoing with other health authorities in the European Union and Australia, where sodium zirconium cyclosilicate is currently under separate regulatory review. About sodium zirconium cyclosilicate (ZS-9) for oral suspension Sodium zirconium cyclosilicate (ZS-9) is an insoluble, non-absorbed compound with a structure that was designed to preferentially trap potassium ions. The unique potassium selectivity of sodium zirconium cyclosilicate enables high in -vitro binding capacity for potassium ions even in the presence of other competing ions. Sodium zirconium cyclosilicate has been studied in three double -blind, placebo controlled trials and in one ongoing 12 month open label clinical trial in patients with hyperkalemia which represents over 1,600 patients treated. Sodium zirconium cyclosilicate is an investigational product that is not currently approved for any indication in any market. About Hyperkalaemia Hyperkalaemia (high potassium levels > 5.0 mEq/L in the blood serum) occurs in 23-47% of patients with advanced chronic kidney disease and/or chronic heart failure, and may lead to cardiac arrest and death (mortality of up to 30% in patients with severe hyperkalaemia if not treated rapidly). Treatment with common heart medicines (RAAS inhibitors) can also be responsible for increases in hyperkalaemia. Current therapeutic options are limited, leaving high unmet medical need. About ZS Pharma ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. ZS Pharma is focused on the development and commercialisation of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. Additional information about ZS Pharma is available at www.zspharma.com. About AstraZeneca in Cardiovascular & Metabolic Disease (CVMD) Cardiovascular, metabolic disease and chronic kidney disease are key areas of focus for AstraZeneca as part of the company's strategy for achieving scientific leadership and returning to growth. Our patient-led strategy is focused on addressing the multiple risk factors facing CVMD and CKD patients at different stages of their disease, with the goal of reducing morbidity and mortality through life changing medicines. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Neil Burrows UK/Global +44 7842 350541 Vanessa Rhodes UK/Global +44 7880 400690 Karen Birmingham UK/Global +44 7818 524012 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Enquiries UK Thomas Kudsk Larsen +44 7818 524185 Nick Stone RIA, CVMD +44 7717 618834 Henry Wheeler Oncology +44 7788 354619 Craig Marks Finance +44 7881 615764 Christer Gruvris ING, Consensus Forecasts +44 7827 836825 US Lindsey Trickett CVMD, Oncology +1 240 543 7970 Mitchell Chan Oncology +1 240 477 3771 Dial / Toll-Free +1 866 381 7277 Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal 27 May 2016 -ENDS-

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tradier Brokerage Data Breach Sparks Legal Probe

Data Breach Drama Hits Tradier Brokerage Picture a broker-dealer like Tradier Brokerage, out in Charlotte, getting its customers' details hanging out there for the world to see. A calamity, courtesy of a cyberattack on their third-party vendor, Etna Software Corp. And we're talking Social Security numbers, tax IDs—emails across Texas and Massachusetts were popping up...

SAMILBIO Gambles on 'Chaeyun' Launch With November Events

Can SAMILBIO's New Products Make a Splash? In a world where skincare is more competitive than a hot dog stand outside a vegan festival, here comes SAMILBIO with their latest offerings. Launching a whitening cream and an acne-fighting gel under the 'Chaeyun' brand, this company isn't just sticking to digital—it's diving into face-to-face consumer interaction. I mean,...

Fluence Energy Faces Class Action Amid $3B Wipeout

The Fluence Fiasco: From Optimism to Legal Battles One minute you're riding high on promises, the next you're grappling with losses that could sink a ship. Fluence Energy (NASDAQ: FLNC) is learning this harsh lesson, as its shareholders eye a nasty $3 billion nosedive and a fresh securities class action lawsuit to boot. Imagine thinking you're poised to tap into an...

InsCorp's Steady Q3 Climb Mirrors Strategic Focus

Riding the Revenue Wave Now we're talking about a bank knowing their business—InsCorp, Inc. recently flaunted a 12% year-on-year revenue bump for 3Q26, a testament to a strategy that's clearly sticking. Still, while those numbers are nice and shiny, the detailed breakdown shows earnings per share (EPS) barely budged from last quarter, coming in at $0.73, just a hair...

KSAT and MSU Boost Lunar Network for Space Growth

Breaking Ground in Space: KSAT and MSU Join Forces Here's a cosmic twist in the world of satellite communications: KSAT and Morehead State University (MSU) are teaming up to expand the lunar frontier. This ain't small potatoes; it's a strategic handshake aimed at beefing up KSAT's lunar network. They're set to amplify support for the growing hunger in deep space...

How Dental Cleaning Frequency Boosts Oral Health

Cleaning Up Confusion on Dental Visits Never thought I'd be waxing poetic about gum health, but here we are. You know what they say, ain't no business like show business—and today's show is all about the pearly whites context, courtesy of Dr. Calvin Despain over in Moses Lake, Washington. Apparently, keeping that grin free from plaque isn't as simple as a quick brush...

HK Boosts Oversight of Building Repairs Post-Blaze

Big Moves After a Tragic Fire Hong Kong's revamping its approach to building maintenance and oversight, clearly in reaction to the horrific Wang Fuk Court blaze last year. That fire didn't just leave scars; it blew open glaring gaps in the city's oversight of building repairs. The government's now jumping into action by launching a raft of measures aimed at preventing...

Gildan Faces Lawsuit: Allegations of Revenue Inflations

Gildan's Revenue Magic Trick or Corporate Roulette? Imagine turning on the news just as Gildan's stock takes a freefall dive. June 16, 2026, didn't just mark another dip on the charts for NYSE: GIL; it sent investors tripping over phone cords as shares plummeted a whopping 18.75%. That's not your everyday market swing, folks. Behind this dramatic drop looms a hefty class...

Class Action Looms Over Tenax Therapeutics Investors

Shareholders in the Crosshairs Every once in a while, the market serves up a cold dish of reality, and folks owning Tenax Therapeutics (NASDAQ:TENX) are facing just that. A class action is casting a long shadow, targeting those who bought in between November 13, 2023, and August 7, 2026. It's the kind of headache that no investor wakes up hoping for. The Allegations: When...

ServiceTitan Faces Investor Fury: Revenue Surprise

A Crippling Blow for ServiceTitan Investors When you're in the investing game long enough, you start to recognize the scent of trouble before it even hits the fan. In the case of ServiceTitan, Inc. (NASDAQ: TTAN), the smell came wafting in strong when the stock took a nosedive on September 9, 2026. Investors were left clutching their portfolios with bewilderment as shares...